These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 25879158

  • 21. A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report.
    Pollack S, Eisenstein I, Mory A, Paperna T, Ofir A, Baris-Feldman H, Weiss K, Veszeli N, Csuka D, Shemer R, Glaser F, Prohászka Z, Magen D.
    Front Immunol; 2021; 12():608604. PubMed ID: 34248927
    [Abstract] [Full Text] [Related]

  • 22. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
    Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC.
    Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086
    [Abstract] [Full Text] [Related]

  • 23. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric Nephrology.
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [Abstract] [Full Text] [Related]

  • 24. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.
    Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, Komada Y, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Fujimura Y, Ikejiri M, Wada H, Miyata T.
    Int J Hematol; 2014 Nov; 100(5):437-42. PubMed ID: 25135378
    [Abstract] [Full Text] [Related]

  • 25. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
    Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, Goodship TH.
    Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
    [Abstract] [Full Text] [Related]

  • 26. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
    Servais A, Frémeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, Grünfeld JP, Lesavre P, Noël LH, Fakhouri F.
    J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
    [Abstract] [Full Text] [Related]

  • 27. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
    Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.
    Front Immunol; 2019 Mar; 10():853. PubMed ID: 31118930
    [Abstract] [Full Text] [Related]

  • 28. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
    Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y.
    PLoS One; 2015 Mar; 10(5):e0124655. PubMed ID: 25951460
    [Abstract] [Full Text] [Related]

  • 29. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts.
    Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, Deng HW, Goodship TH.
    J Med Genet; 2005 Nov; 42(11):852-6. PubMed ID: 15784724
    [Abstract] [Full Text] [Related]

  • 30. Plasmatherapy in atypical hemolytic uremic syndrome.
    Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T.
    Semin Thromb Hemost; 2010 Sep; 36(6):673-81. PubMed ID: 20865645
    [Abstract] [Full Text] [Related]

  • 31. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
    Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
    [Abstract] [Full Text] [Related]

  • 32. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.
    Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP.
    Blood; 2008 Dec 15; 112(13):4948-52. PubMed ID: 18796626
    [Abstract] [Full Text] [Related]

  • 33. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
    Bhattacharjee A, Reuter S, Trojnár E, Kolodziejczyk R, Seeberger H, Hyvärinen S, Uzonyi B, Szilágyi Á, Prohászka Z, Goldman A, Józsi M, Jokiranta TS.
    J Biol Chem; 2015 Apr 10; 290(15):9500-10. PubMed ID: 25659429
    [Abstract] [Full Text] [Related]

  • 34. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
    Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT.
    Blood; 2013 Jul 11; 122(2):282-92. PubMed ID: 23692858
    [Abstract] [Full Text] [Related]

  • 35. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA.
    J Immunol; 2015 Jun 01; 194(11):5129-38. PubMed ID: 25917093
    [Abstract] [Full Text] [Related]

  • 36. Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.
    Martin Merinero H, Subías M, Pereda A, Gómez-Rubio E, Juana Lopez L, Fernandez C, Goicoechea de Jorge E, Martin-Santamaria S, Cañada FJ, Rodríguez de Córdoba S.
    Blood; 2021 Jun 24; 137(25):3484-3494. PubMed ID: 33651882
    [Abstract] [Full Text] [Related]

  • 37. Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
    Merinero HM, García SP, García-Fernández J, Arjona E, Tortajada A, Rodríguez de Córdoba S.
    Kidney Int; 2018 Feb 24; 93(2):470-481. PubMed ID: 28941939
    [Abstract] [Full Text] [Related]

  • 38. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
    Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN.
    J Biol Chem; 2011 Apr 01; 286(13):11082-90. PubMed ID: 21270465
    [Abstract] [Full Text] [Related]

  • 39. A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.
    Ding Y, Zhao W, Zhang T, Qiang H, Lu J, Su X, Wen S, Xu F, Zhang M, Zhang H, Zeng C, Liu Z, Chen H.
    Sci Rep; 2017 Jul 20; 7(1):6004. PubMed ID: 28729648
    [Abstract] [Full Text] [Related]

  • 40. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
    Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V.
    Kidney Int; 2010 Feb 20; 77(4):339-49. PubMed ID: 20016463
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.